redhillbio.com (RDHL): Debt to Book Capitalization Ratio

RedHill Biopharma R&D expenditures are currently focused on adapting existing drugs, which is reflected in the financial leverage chart based on balance sheet capitalization on GURU.Markets; this parameter has stabilized at 0.00. High physician confidence in GI treatment innovations and an aggressive employee incentive system via RSUs provide the company with resilience and commercial efficiency.

RDHL RedHill Biopharma Ltd.: Debt to Book Value in the range 07/04/2022 - 10/29/2026

Comprehensive metric breakdowns and analytics for redhillbio.com (RDHL)

- current price and projected stock value:

Stock Price RedHill Biopharma Ltd.|RDHL - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value RedHill Biopharma Ltd.|RDHL - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share RedHill Biopharma|RDHL - Company Net Assets|Market Capitalization to Book Value Ratio redhillbio.com|RDHL - Company Total Assets

- debt and solvency information:

Total Debt to Equity Ratio RedHill Biopharma|RDHL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital RedHill Biopharma Ltd.|RDHL - Company Total Indebtedness|Debts to Book Capitalization RedHill Biopharma Ltd.|RDHL - Long-Term Debt Volume|Company Current Liabilities RedHill Biopharma

Basic company analysis:RedHill RDHL

RedHill Biopharma (RDHL) relies on patent protection for its gastrointestinal drugs, which is weakening under pressure from generics. This ratio compares total liabilities to the amount of equity to identify hidden asset degradation. The metric allows for an assessment of the company's resilience to market shocks and bankruptcy risks. The investor determines the balance between debt leverage and capital preservation. By analyzing the financing structure—debt to book capitalization—one can observe the erosion of the business's financial moat.

Analysis of competing companies

Debts to Book Capitalization PHAT (Phathom Pharmaceuticals)|Debts to Book Capitalization ternspharma.com TERN|IRWD - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio CURX (Curanex Pharmaceuticals Inc)|immuron.com.au (IMRN) - Debt to Book Capitalization Ratio|Debt to Book Value Evoke Pharma Inc|ENTO (Entero Therapeutics Inc.) - Debts to Book Capitalization|Debts to Book Capitalization Palisade Bio Inc.|Debt to Book Value JAGX (Jaguar Health)|BIOR (Biora Therapeutics Inc.) - Debt to Net Assets Ratio|Debts to Book Capitalization MORF (Morphic Holding Inc)